Literature DB >> 22375958

Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis.

Peter Sun1, Michael Kohrman, Jamae Liu, Amy Guo, Jaqueline Rogerio, Darcy Krueger.   

Abstract

OBJECTIVE: To examine the outcomes following resection of subependymal giant cell astrocytoma (SEGA) among patients with SEGA-associated tuberous sclerosis complex (TSC).
METHODS: Using three large US national healthcare claims databases, we retrospectively examined the outcomes of SEGA surgery among TSC patients who underwent SEGA surgery between 2000 and 2009. The examined outcomes were: prevalence rates of post-surgery SEGA, repeated SEGA surgery, and postoperative complications (surgical procedure complications, nervous system complications, postoperative infections, complications of subdural empyemas, and complications of epidural abscesses). Descriptive data analysis and two-sided one sample t-test for mean or proportion were used to assess the characteristics of patients and the outcomes of SEGA surgery.
RESULTS: The selected patients (N = 47) had a mean age of 11.6 years at their first SEGA surgery and 66% were male. During the third through twelfth months following surgery, 34% had post-surgery SEGA (diagnosis) and 12% underwent repeated SEGA surgeries. During the first post-surgery year, 48.9% of patients developed postoperative complications (34.0% had complications relating to the surgical procedure, 12.8% had nervous system complications, 6.4% developed postoperative infections, 17.0% had complications of subdural empyemas, and 2.1% had complications of epidural abscesses).
CONCLUSIONS: SEGA surgery was associated with statistically significant risks of developing post-surgery SEGA, requiring repeated SEGA surgery and developing postoperative complications. Future efforts in reducing these outcomes, either through improving surgical procedures or through alternative treatments, are urgently needed. LIMITATIONS: This study has its limitation in data source representativeness and measurement accuracy.

Entities:  

Mesh:

Year:  2012        PMID: 22375958     DOI: 10.1185/03007995.2012.658907

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  13 in total

1.  Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex.

Authors:  Darcy A Krueger
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

Review 2.  Nervous system (NS) Tumors in Cancer Predisposition Syndromes.

Authors:  Prabhumallikarjun Patil; Bojana Borislavova Pencheva; Vinayak Mahesh Patil; Jason Fangusaro
Journal:  Neurotherapeutics       Date:  2022-09-02       Impact factor: 6.088

Review 3.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

4.  Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis.

Authors:  Paolo Frassanito; Carolina Noya; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2020-09-25       Impact factor: 1.475

Review 5.  Innovative research methods for studying treatments for rare diseases: methodological review.

Authors:  Joshua J Gagne; Lauren Thompson; Kelly O'Keefe; Aaron S Kesselheim
Journal:  BMJ       Date:  2014-11-24

6.  Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.

Authors:  Xiaoyan Shawn Li; Steve Deitelzweig; Allison Keshishian; Melissa Hamilton; Ruslan Horblyuk; Kiran Gupta; Xuemei Luo; Jack Mardekian; Keith Friend; Anagha Nadkarni; Xianying Pan; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2017-03-16       Impact factor: 5.249

Review 7.  Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.

Authors:  David Neal Franz
Journal:  Biologics       Date:  2013-10-10

8.  Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

Authors:  David N Franz; Karen Agricola; Maxwell Mays; Cindy Tudor; Marguerite M Care; Katherine Holland-Bouley; Noah Berkowitz; Sara Miao; Séverine Peyrard; Darcy A Krueger
Journal:  Ann Neurol       Date:  2015-11-09       Impact factor: 10.422

9.  Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.

Authors:  Xiaoyan Li; Allison Keshishian; Melissa Hamilton; Ruslan Horblyuk; Kiran Gupta; Xuemei Luo; Jack Mardekian; Keith Friend; Anagha Nadkarni; Xianying Pan; Gregory Y H Lip; Steve Deitelzweig
Journal:  PLoS One       Date:  2018-01-26       Impact factor: 3.240

10.  Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey.

Authors:  Anne M Rentz; Anne M Skalicky; Zhimei Liu; David W Dunn; Michael D Frost; Jo Anne Nakagawa; Judith Prestifilippo; Qayyim Said; James W Wheless
Journal:  J Patient Rep Outcomes       Date:  2018-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.